Navigation Links
EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
Date:2/26/2008

ROCKVILLE, Md., Feb. 26 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that James S. Burns, President and Chief Executive Officer, will present a Corporate overview at the Jesup & Lamont Emerging Growth Stock Conference, which will be held at the Disney Contemporary Resort in Orlando, Florida on Thursday, February 28, 2008. Mr. Burns is scheduled to present at 1:35 p.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO)

Mr. Burns' live presentation will not be web cast, but will be available through the Company's web site at http://www.entremed.com.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. Panzem(R) (2-methoxyestradiol) NCD is also in multiple Phase 2 studies in oncology patients. Additionally, ENMD-1198, a novel anticancer drug, is in Phase 1 studies in advanced cancers. The Company has approved IND applications for Panzem(R) in rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora- angiogenesis inhibitor, for cancer. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoi
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. EntreMed Receives Deloitte Technology Fast 50 Award
2. EntreMed to Present at the Bio 2007 Investor Forum
3. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
4. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
5. EntreMed Reports Third Quarter 2007 Financial Results
6. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
7. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
8. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
9. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
10. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
11. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Calling all runners, walkers and everyone who wants to join ... annual “Lyme Walk & Run” will be held Sunday, April ... hosted by Lyme Research Alliance (LRA) & Tick-Borne ... and education about Lyme and other tick-borne diseases. , ... feature 5K and 10K runs and one-mile and three-mile Walks ...
(Date:3/31/2015)... Many people, including the ones with physical ... cycling are only for able-bodied participants. , A ... aims to change that thinking. , The program, ... Adaptive Sports Expo on Saturday, April 11 (10 a.m. ... Hollywood. , The event will showcase a wide ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Indosoft, developer of ... Asterisk 1.4 support in development of their 5.x line. The ... Asterisk has been deployed around the world for more than ... 1.4 as a telephony platform, Q-Suite can fully embrace newer ... quality call center software on Asterisk for more than a ...
(Date:3/31/2015)... KL Malaysia (PRWEB) March 31, 2015 ... need and requirement for education in a drastically different ... way in which learning and training content is being ... is being impacted by technology in an unprecedented way ... everyone, said Wemel Cumavoo, co-founder and CEO, My Mobile ...
(Date:3/31/2015)... March 31, 2015 The Walk a Mile ... GMO controversy , just kicked off their 3rd research sequence. ... equivalence.” , “ Substantial Equivalence was and is a ... Eric Battersby, Director at Change The World Films. “We ... well before GMOs even entered our food supply, just to ...
Breaking Medicine News(10 mins):Health News:Lyme Research Alliance & Tick-Borne Disease Alliance to Kick-Off 1st “Lyme Walk & Run” Event, April 26 2Health News:Memorial Healthcare System's Adaptive Sports Expo Encourages Physically Challenged To Go Beyond Perceived Limitations 2Health News:Indosoft Announces End of Life for Asterisk 1.4 Support in Q-Suite 5 Call Center Software 2Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 2Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 3Health News:The Walk a Mile Project Launches New Research Sequence on Substantial Equivalence of GMOs 2
... researchers led by scientists at Scripps Institution of Oceanography ... a tropical marine organism known to produce substances potentially ... cyanobacteria are some of the oldest forms of life ... blooms causes a threat to humans and animals. But ...
... 9 (HealthDay News) -- Could gastric bypass weight-loss surgery raise ... finding from a group of Swedish researchers who were slated ... Disease Week conference in Chicago. A team from the ... underwent primary bariatric surgery between 1980 and 2006. The patients ...
... Overdiagnosis and overtreatment of pulmonary embolism is a problem in ... use of computed tomography pulmonary angiography (CTPA), a new study ... blood clot in the lungs. CTPA was introduced in 1998 ... rapidly, according to background information in the study by Boston ...
... with torture is prohibited by international law and professional ... for doctors to do, argue two bioethicists. Their timely ... as news of the trail leading to the death ... Bay who were subject to "enhanced interrogation techniques," which ...
... Digestive Disease Week (DDW) is the largest international ... fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. ... Study of Liver Diseases, the American Gastroenterological Association ... and the Society for Surgery of the Alimentary ...
... MONDAY, May 9 (HealthDay News) -- An estimated one in ... an autism spectrum disorder, a new study says -- figures ... Estimates of autism prevalence in the United States generally ... or less than 1 percent. But those numbers may ...
Cached Medicine News:Health News:Genome of marine organism reveals hidden secrets 2Health News:Genome of marine organism reveals hidden secrets 3Health News:Risk for Problem Drinking May Rise After Gastric Bypass 2Health News:Scan Technology Tied to Overtreatment of Clots in Lungs 2Health News:A grim dilemma: Treating the tortured prisoner 2Health News:A grim dilemma: Treating the tortured prisoner 3Health News:UNC research highlights at 2011 Digestive Disease Week 2Health News:S. Korean Study Suggests Autism Rate May Be Much Higher 2Health News:S. Korean Study Suggests Autism Rate May Be Much Higher 3
(Date:3/31/2015)... -- Accelerated orthodontic treatment will be a featured ... Annual Session, May 15-19, as seven of the ... ® . Manufactured by OrthoAccel ® Technologies, ... a FDA-cleared, Class II medical device that speeds ... percent with just 20 minutes of daily use. ...
(Date:3/31/2015)... -- SCILEX Pharmaceuticals, Inc., a company engaged in the development ... pain, today announced that ITOCHU CHEMICAL FRONTIER Corporation (ICF, ... ITOCHU Corporation ( Tokyo : 8001; OTC-PINK: ... trading companies) in Japan , has ... closely with SCILEX as an advisor and development partner ...
(Date:3/31/2015)... , March 31, 2015  SynCardia Systems, Inc. has ... (IDE) clinical study on the effective use of its ... The FDA approval will ... as 30 heart failure patients. Patients enrolled in this ... as a bridge to a donor heart transplant. ...
Breaking Medicine Technology:Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 2Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 3SCILEX Pharmaceuticals Announces Strategic Investment By ITOCHU CHEMICAL FRONTIER Corporation 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 3FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 4
... patients will be tested,to determine the prevalence of ... major cooperative effort between the Alpha-1 Foundation,and the ... principal investigator is Robert A. Sandhaus, MD, PhD, ... and Research Center,in Denver. Sandhaus is also the ...
... Dec. 6 DURECT Corporation,(Nasdaq: DRRX ... III trial for Remoxy,had successfully met its ... the U.S. Food and Drug Administration (FDA) ... investigational drug based on,DURECT,s patented ORADUR(TM) technology, ...
Cached Medicine Technology:Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 2Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 3Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 2Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 3Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 4
Our smallest port is available with either a COOK Peel-Away or COOK Micropuncture Introducer Set....
Small size means convenient set up in any cath lab. ,System so versatile it can be mounted on I.V. pole or bedside, or bagged in sterile field....
... vascular access. Hollow stylet design ... puncture with two-part needle. Initial ... while maintaining thumb position on ... hub of the stylet. Supplied ...
Used for placement of .035 inch (0.89 mm) or .038 inch (0.97 mm) diameter wire guides into the vascular system when a small 21 gage needle stick is desired....
Medicine Products: